In recent years, the research group at UCIBIO - Laboratory of Toxicology, Faculty of Pharmacy, University of Porto - has focused on studying metabolic reprogramming in urological cancers to identify potential biomarkers with different clinical applications, including diagnosis, prognosis, and response to treatment. The most recent study aimed to characterise the metabolic signature of renal cell carcinoma (RCC) by analysing the metabolome of renal tumour and adjacent non-tumour tissues, as well as urine samples collected from the same patients.